Date: 2017-03-09
Type of information: Research agreement
Compound: synergistic drug combinations
Company: Galapagos (Belgium) Pharnext (France)
Therapeutic area: Neurodegenerative diseases - Neuroinflammatory diseases
Type agreement: research - R&D
Action mechanism:
Disease: neurodegenerative diseases, immunoinflammatory diseases
Details:
- • On March 9, 2017, Pharnext announced a research and development (R&D) agreement with Galapagos. The main goal of this agreement is to generate an additional pipeline of novel synergistic drug combinations in a broad set of indications.
The agreement is based on both partners’ R&D capabilities while it will initially be based on Pharnext’s disruptive
technological platform, Pleotherapy™. Until now this platform has enabled the discovery and patenting of low dose combinations of approved drugs repositioned in a new indication and aims to develop more rapidly, safer
and more efficacious treatments for unmet medical needs.
The collaboration agreement with Galapagos highlights another outstanding feature of Pharnext’s platform: its
ability to reinforce the potential of new candidate drugs.
- For a given new preclinical or clinical candidate drug provided by Galapagos, Pharnext’s technology will aim to identify already approved drugs which could be combined at low doses with this new candidate in order to safely increase its efficacy.
This agreement will not only concern therapeutic indications that were primarily envisioned by Galapagos, but also others that Pharnext will identify. Expanding their market to new indications as well as generating new patents should significantly increase the value of the new compounds.
Pharnext’s cutting-edge approach is applicable to a broad spectrum of diseases. Therapeutic indications that will
be considered in this R&D agreement will notably include immunoinflammatory and neurodegenerative
disorders which represent potentially substantial markets. Each of the companies will have priority on indications
which will have been previously allocated.
Intellectual property with regard to synergistic drug combinations generated by the R&D collaboration will be
jointly owned by Pharnext and Galapagos.
Financial terms: Financial terms of the agreement are not disclosed.
Latest news:
Is general: Yes
